随着马斯克明确给出脑机接口设备的量产时间表，这一前沿赛道正从实验室的科学探索加速走向商业化落地，行业或将迎来从"医疗试验品"向"大众消费品"跨越 的关键转折点。 2026年A股开盘首日，脑机接口板块表现强势。倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗等多股20CM涨停，市场资 金对脑机接口商业化前景展现出极高预期。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 涨跌 | 换手率 | | --- | --- | --- | --- | --- | --- | | 688108 | 赛诺医疗 | 23.09 | 20.01% | 3.85 | 14.83% | | 300238 | 元 | 16.62 | 20.00% | 2.77 | 13.53% | | 300753 | 爱朋医疗 | 33.30 | 20.00% | 5.55 | 21.10% | | 301363 | 美好医疗 | 28.86 | 20.00% | 4.81 | 1.93% | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 12.10 | 3.36% | | 300003 | ...

2026年A股开盘首日，脑机接口概念表现活跃。截至发稿，倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗20cm 涨停，创新医疗、南京熊猫10CM涨停，博拓生物、狄耐克等涨超10%。 开源证券最新研报表示， 上述行业事件印证了脑机接口技术预计将在2026年迈向商业化，并从医疗刚需向AI应用、机器人等多领域渗透 。 Neuralink的规模化生产预期+自动化手术方案，以及Merge布局新一代超声波脑机接口技术具备双重意义。一方面，这标志着脑机接口从临 床验证阶段开始向商业化规模化阶段迈进，推动脑机接口从"医疗试验工具"到"可普及产品"的落地；另一方面，未来随着技术方案成熟度的 进一步提升，也将为Neuralink脑机接口与特斯拉Optimus人形机器人的协同应用奠定基础。 该机构进一步表示，脑机接口行业正处于技术突破、政策支持、机器人生态协同预期等多重因素驱动下的高增蓄势期，根据Precedence Research数据， 预计到2034年全球脑机接口市场规模将增长到约124亿美元 ，2025-2034年CAGR为17%。 在近期Neuralink规模化量 产预期和技术突破的催化下， ...

Core Viewpoint - The article highlights the resurgence of hardware startups in Shenzhen, particularly in the context of "hardware + going global," showcasing a vibrant investment scene and innovative products in various sectors such as robotics, sleep health, and smart wearables [2][10]. Group 1: Event Overview - The "X-Day" event held on February 4 in Shenzhen attracted significant attention, with six startups presenting their innovations to a packed audience of investors [2]. - The participating companies included Benmo Technology, Subrain Technology, Dream Innovation, Natural AI, Laimu Technology, and Ruiman Intelligent, covering cutting-edge fields like intelligent robotics and smart apparel [2]. Group 2: Company Highlights - Benmo Technology, founded in 2020, has completed Series C financing and launched the world's first detachable dual-person robot, gaining substantial media attention [4]. - Subrain Technology, established in October 2023, focuses on an intelligent sleep aid device that reduces average sleep onset time by 20 to 30 minutes, having completed three rounds of financing in under two months [4]. - Dream Innovation's core product, the smart sleep lamp "SunflowerX," aims to facilitate effortless sleep and natural awakening, and has secured seed funding from Xbot Park in Chongqing [5]. - Natural AI introduced a full-domain AI temperature control garment, aiming to integrate AI into wearable technology, and is set to deliver its first batch of B-end products [6]. - Laimu Technology, which has completed several rounds of financing totaling hundreds of millions, focuses on the overseas market potential for its lawn mowing robots [6]. - Ruiman Intelligent, established in 2017, specializes in ultra-lightweight humanoid robotic arms and emphasizes the necessity of international expansion for Chinese intelligent companies [7]. Group 3: Investment Landscape - The event showcased a strong presence of venture capital firms, indicating a booming interest in hardware projects [9]. - The trend of hardware companies going global is driven by successful examples like DJI and others, which have provided impressive returns to investors [10]. - The article notes that new-generation hardware products are inherently designed for international markets, leveraging Shenzhen's supply chain advantages [10]. Group 4: Future Prospects - The "X-Day" event is set to continue, with a focus on innovative early-stage projects in frontier sectors, aiming to identify potential new unicorns [13]. - The article emphasizes a shift in perception of Chinese products from "Made in China" to "Created by China," reflecting advancements in technology and innovation [13].

Summary of Brain-Computer Interface (BCI) Industry Research Report Industry Overview - The brain-computer interface (BCI) industry in China is benefiting from multi-faceted support, including technological innovations from various enterprises and research institutions, as well as policy support from government bodies such as the Ministry of Industry and Information Technology, the National Healthcare Security Administration, and the National Medical Products Administration, which is expected to accelerate clinical trials and approval processes [1][2][11]. Key Points and Arguments - **Classification of BCI Technologies**: BCI technologies are categorized into four types based on hardware access methods: invasive, semi-invasive, non-invasive, and interventional, each suitable for different levels of neurological disorders and rehabilitation [1][4]. - **Market Growth**: The domestic BCI market is projected to have a compound annual growth rate (CAGR) of 13.5% over the next five years, although challenges such as unclear product forms, clinical risks, and ethical issues may hinder market scaling [1][6]. - **Medical Applications**: BCI technology is primarily applied in healthcare, focusing on the rehabilitation of motor, language, visual, and cognitive impairments, with motor function rehabilitation being the most clinically advanced area [1][8]. - **Technological Innovations**: Key advancements include the shift from rigid to flexible electrodes, which enhance biocompatibility and reduce trauma to brain tissue, as well as breakthroughs in chip throughput and decoding algorithms [9][10]. Company Insights - **Meihua Medical Company**: The company has rapidly expanded its business from supplying home respiratory device components to entering the implanted BCI device market, leveraging its expertise in cochlear implants and CGM insulin pens. It is expected to see accelerated revenue growth in the upcoming quarters [5][19]. - **Notable Companies in the BCI Industry**: Key players include JieTi Medical, Tiger Technology, New Intelligence, and BoRuiKang, each involved in various aspects of the BCI supply chain, from electrode chip production to clinical trials [12]. Challenges and Risks - **Market Penetration Issues**: The penetration rate of BCI products is affected by high costs and the risks associated with surgical procedures, leading to cautious attitudes among patients and families [7]. - **Regulatory and Ethical Concerns**: The approval timeline for invasive and semi-invasive products may be delayed due to clinical risks and ethical considerations, impacting market growth [6]. Policy Environment - **Government Support**: A series of policies have been introduced to support the BCI industry, including healthcare reimbursement for innovative medical consumables and the establishment of industry standards, which are expected to catalyze market growth [11][18]. Future Outlook - The BCI industry is poised for significant growth, driven by technological advancements, supportive policies, and increasing applications in both medical and non-medical fields, including gaming and robotics [2][3].